Human Immunodeficiency Virus (HIV) attacks the immune system, specifically targeting CD4+ T cells, which weakens the body's ability to fight off infections. In pregnant women, physiological changes slightly alter immune function, but the primary clinical concern is the risk of vertical transmission to the foetus. HIV is transmitted through unprotected sexual contact, exposure to infected blood, and from mother to child during pregnancy, childbirth, or breastfeeding.
In the Nigerian context, antenatal clinics serve as the primary gateway for identifying positive status through routine provider-initiated counselling and testing (PICT). Midwives must approach testing with empathy, maintaining strict confidentiality to encourage disclosure and adherence to lifelong treatment. Early diagnosis transforms pregnancy outcomes, protecting both maternal health and the unborn child.
Mother-to-child transmission, also known as vertical transmission, can occur at three distinct biological junctures if appropriate interventions are absent:
High maternal viral load remains the single greatest risk factor for transmission. Interventions such as antiretroviral drugs and safe delivery practices aim to reduce this viral presence to undetectable levels.
Antiretroviral therapy (ART) is the cornerstone of managing HIV in pregnancy. Current guidelines recommend lifelong combination antiretroviral therapy (cART) for all pregnant and breastfeeding women living with HIV, regardless of their CD4 count or clinical stage.
A standard first-line regimen typically includes a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs), such as Tenofovir and Lamivudine, paired with an integrase strand transfer inhibitor like Dolutegravir. This combination suppresses viral replication rapidly, preserves maternal immune function, and drives the viral load down to undetectable levels. Midwives play a crucial role in counseling mothers on the absolute necessity of daily, uninterrupted adherence to prevent drug resistance.
The global framework for Prevention of Mother-to-Child Transmission (PMTCT) relies on a comprehensive, multi-pronged approach that extends far beyond dispensing medication.
Implementing these steps successfully requires community engagement to reduce the stigma that often prevents women from seeking timely care.
Intrapartum care for an HIV-positive woman requires balancing standard obstetric management with specific risk-reduction practices. Midwives must review the woman's recent viral load results and adherence history upon admission to the labour ward. Routine invasive procedures, such as artificial rupture of membranes or the use of fetal scalp electrodes, should be minimized to avoid exposing the baby to maternal blood.
Elective Caesarean section may be recommended if the mother's viral load is high or unknown near term. For women with suppressed viral loads, vaginal delivery remains safe and appropriate. Universal precautions must be strictly observed during all stages of childbirth. Postnatally, the midwife ensures the newborn receives immediate antiretroviral prophylaxis—such as syrup Nevirapine or Zidovudine—usually commenced within hours of birth.
Infant feeding counseling requires a delicate balance between providing optimal infant nutrition and preventing postnatal HIV transmission. In many resource-limited settings, exclusive breastfeeding combined with maternal ART is recommended because it offers the best child survival advantage while keeping transmission risks extremely low. Mixed feeding—giving breast milk alongside water, formula, or solid food early on—is strongly discouraged because it damages the infant's gut lining and increases viral transmission.
Early Infant Diagnosis (EID) is critical because standard antibody tests are ineffective due to maternal antibodies crossing the placenta. Instead, infants undergo Virological testing using Dried Blood Spot (DBS) PCR typically at six weeks of age. Midwives guide mothers through these testing milestones to ensure prompt treatment if an infant tests positive.